The global aseptic filling machine market, valued at USD 1,733 million in 2025, is projected to reach USD 1,910 million in 2026 and USD 3,591 million by 2035, representing a CAGR of 7.27% during the forecast period 2026 to 2035. Growth is being supported by increasing production of sterile biologics and injectable therapies, tighter contamination-control expectations, wider use of ready-to-use primary containers, and continued investment in automated and robotic fill / finish infrastructure. In...

The global biostatistics and statistical programming services market, valued at USD 3.28 billion in 2025, is estimated at USD 3.52 billion in 2026 and is projected to reach USD 6.65 billion by 2035, representing a CAGR of 7.3% during the forecast period. Market growth is supported by rising statistical workload per clinical-development programs, flexible outsourcing of specialist biometrics capacity, and expanding regulatory and post-market statistical requirements. North America leads the globa...

The global prenatal diagnostic software market is estimated at USD 290.1 million in 2026 and is projected to reach USD 779.6 million by 2035, expanding at a CAGR of 11.6% during 2026-2035. Growth is being supported by broader prenatal screening, increasing use of software-assisted fetal imaging, and greater integration of risk assessment, reporting and clinical workflow tools.

The global artificial organs and bionics market, valued at USD 29.40 billion in 2025, is estimated at USD 31.46 billion in 2026 and is projected to reach USD 54.13 billion by 2035, representing a CAGR of 6.21% during the forecast period 2026 to 2035. Growth is being supported by sustained demand for long-duration organ support and the wider use of automated, wearable and restorative systems across chronic and irreversible conditions. Specialty clinics & rehabilitation centers represent the large...

The antibody drug conjugates market, valued at USD 15.47 billion in 2025, is projected to reach USD 18.57 billion in 2026 and USD 43.56 billion by 2035, representing a CAGR of 9.9% during the forecast period 2026 to 2035. Market growth is expected to be supported by the expanding global oncology therapeutics landscape, increasing commercialization of targeted cancer therapies, sustained industry investment, and the rising adoption of advanced treatment modalities across healthcare systems. Breas...

The global bioinformatics market was valued at USD 17.3 billion in 2025 and is estimated at USD 19.8 billion in 2026. It is projected to reach USD 52.6 billion by 2035, representing an 11.5% CAGR from 2026 to 2035. Expanding multi-omics workloads, production-grade analytical workflows and clinical interpretation needs are increasing demand for specialized bioinformatics platforms and services. Generalized knowledge management tools dominate the knowledge management tools segment in 2026; special...

The targeted alpha therapy market was valued at USD 0.22 billion in 2025 and is estimated to reach USD 0.20 billion in 2026. The market is projected to reach USD 4.39 billion by 2035, growing at a CAGR of 41.0% during 2026-2035. Market growth is expected to accelerate as late-stage Ac-225 and Pb-212 therapies advance toward commercialization alongside expanding radiopharmaceutical treatment and isotope infrastructure. Targeted alpha therapy (TAT) is attracting sustained oncology interest because...

The global subcutaneous biologics market, valued at USD 250.6 billion in 2025, is projected to reach USD 267.6 billion in 2026 and USD 233.0 billion by 2035, during the forecast period 2026 to 2035. The long-term decline in value is primarily linked to patent expiry and revenue erosion across a number of currently marketed originator biologics, even as clinical activity, subcutaneous conversion programs and patient adoption continue to expand. In January 2026, FDA approved DARZALEX FASPRO® in c...

The global peptide synthesis market, valued at USD 3.8 billion in 2025, is projected to reach USD 4.4 billion in 2026 and USD 7.0 billion by 2035, at a CAGR of 5.2% during the forecast period 2026 to 2035. This market size refers to the peptide API contract manufacturing opportunity rather than the broader market for peptide synthesizers, reagents, consumables or research-only peptide products. The market growth is being supported by the expanding pipeline of peptide therapeutics, rising commerc...

The cytotoxic drugs and HPAPI manufacturing market, valued at USD 13.98 billion in 2025, is projected to grow to USD 15.59 billion in 2026 and USD 46.41 billion by 2035, representing a CAGR of 12.89% during the forecast period 2026 to 2035. The growth is being supported by rising demand for targeted oncology therapies, antibody-drug conjugates (ADCs), highly potent small molecules and other complex drug candidates that require specialized containment, process development and good manufacturing p...

The global cell and gene therapy CRO market, valued at USD 1.9 billion in 2025, is estimated to reach USD 2.1 billion in 2026 and USD 3.5 billion by 2035, representing a CAGR of 5.7% during the forecast period. The market growth is being supported by the expanding pipeline of advanced therapies, increasing complexity of cell and gene therapy clinical development, growing outsourcing of specialized research activities and rising requirements for regulatory, clinical-operational, safety and data-m...

The global wearable injectors market, valued at USD 6.5 billion in 2025, is projected to reach USD 6.8 billion in 2026 and USD 13.0 billion by 2035, representing a CAGR of 7.4% during the forecast period 2026 to 2035. The total market combines two clinically and commercially distinct segments: wearable injectors used for insulin delivery and wearable injectors used for non-insulin drugs. The insulin segment is centered on diabetes management and continuous or automated insulin delivery, while th...

The global acute ischemic stroke therapeutics market, valued at USD 1,920 million in 2025, is projected to reach USD 2,077 million in 2026 and USD 3,917 million by 2035, representing a CAGR of 7.3% during the forecast period from 2026 to 2035. In terms of the type of molecule, biologics hold the highest share (nearly 55%) of the current market. By drug class, thrombolytics dominate the current acute ischemic stroke therapeutics market.

The peptide therapeutics contract manufacturing market was valued at USD 3.38 billion in 2025 and is estimated at USD 3.91 billion in 2026. It is projected to reach USD 10.79 billion by 2035, representing a CAGR of 11.94% during 2026-2035. Growth is being supported by the expanding commercial pipeline for peptide therapeutics and greater reliance on specialized external manufacturing capacity.

The global veterinary vaccines market, valued at USD 12.8 billion in 2025, is projected to reach USD 13.4 billion in 2026 and USD 22.0 billion by 2035, representing a CAGR of 5.69% during the forecast period 2026 to 2035. Around 60% of the known infectious diseases are zoonotic in origin (transmitted from animals to humans), responsible for 2.5 billion disease cases and 2.7 million human deaths every year, across the globe. Vaccination of animals helps protect animals as well as human population...

The Europe AI in clinical trials market, valued at USD 0.90 billion in 2025, is projected to reach USD 1.01 billion in 2026 and USD 2.76 billion by 2035, with a CAGR of 11.8% during the forecast period, 2026 to 2035. In June 2026, Owkin entered a multiyear collaboration with Sanofi to build K Pro biopharma AI agents backed by a five-year K Pro license. K Pro uses multimodal patient data and agentic AI to support decisions from early discovery through clinical development. In April 2026, Boehring...

The North America AI in clinical trials market, valued at USD 0.80 billion in 2025, is projected to reach USD 0.91 billion in 2026 and USD 2.58 billion by 2035, with a CAGR of 12.4% during the forecast period, 2026 to 2035. Based on the deployment mode, cloud-based AI solutions capture the largest share of the current market, and the trend is unlikely to change in the future.

The GLP-1 receptor agonist market size, valued at USD 78 billion in 2025, is projected to reach USD 101.4 billion in 2026 and USD 180 billion by 2035, representing a CAGR of 6.6% during the forecast period 2026 to 2035. Growth is concentrated in three visible shifts: oral small-molecule formulations are gaining share against long-established injectable therapies, expanding patient populations beyond type 2 diabetes into obesity and adjacent metabolic conditions are pulling in new prescriber and...

The global radiopharmaceutical logistics market, valued at USD 0.99 billion in 2025, is projected to reach USD 1.10 billion in 2026 and USD 3.13 billion by 2035, representing a CAGR of 12.31% during the forecast period 2026 to 2035. Market growth is expected to be supported by the expanding commercialization of diagnostic and therapeutic radiopharmaceuticals, increasing nuclear-medicine and treatment-site capacity, greater reliance on specialist outsourced logistics providers, and rising require...

The global pharmaceutical contract manufacturing market size, valued at USD 100.3 billion in 2025, is projected to reach USD 104.4 billion in 2026 and USD 155.4 billion by 2035, with a CAGR of 4.5% during the forecast period 2026 to 2035. This market is growing steadily, driven by the increased extent of outsourcing, thereby accelerating the time-to-market. In terms of API potency, low potent API sub-segment currently holds around 85% of the market share, due to their widespread application, low...